Literature DB >> 24430184

Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Hua Li, Mingjia Tan, Lijun Jia, Dongping Wei, Yongchao Zhao, Guoan Chen, Jie Xu, Lili Zhao, Dafydd Thomas, David G Beer, Yi Sun.   

Abstract

Cullin-RING ligases (CRLs) are a family of E3 ubiquitin ligase complexes that rely on either RING-box 1 (RBX1) or sensitive to apoptosis gene (SAG), also known as RBX2, for activity. RBX1 and SAG are both overexpressed in human lung cancer; however, their contribution to patient survival and lung tumorigenesis is unknown. Here, we report that overexpression of SAG, but not RBX1, correlates with poor patient prognosis and more advanced disease. We found that SAG is overexpressed in murine KrasG12D-driven lung tumors and that Sag deletion suppressed lung tumorigenesis and extended murine life span. Using cultured lung cancer cells, we showed that SAG knockdown suppressed growth and survival, inactivated both NF-κB and mTOR pathways, and resulted in accumulation of tumor suppressor substrates, including p21, p27, NOXA, and BIM. Importantly, growth suppression by SAG knockdown was partially rescued by simultaneous knockdown of p21 or the mTOR inhibitor DEPTOR. Treatment with MLN4924, a small molecule inhibitor of CRL E3s, also inhibited the formation of KrasG12D-induced lung tumors through a similar mechanism involving inactivation of NF-κB and mTOR and accumulation of tumor suppressor substrates. Together, our results demonstrate that Sag is a Kras-cooperating oncogene that promotes lung tumorigenesis and suggest that targeting SAG-CRL E3 ligases may be an effective therapeutic approach for Kras-driven lung cancers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430184      PMCID: PMC3904615          DOI: 10.1172/JCI70297

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.

Authors:  Katrina M Bockbrader; Mingjia Tan; Yi Sun
Journal:  Oncogene       Date:  2005-11-10       Impact factor: 9.867

3.  The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2.

Authors:  T Kamura; M N Conrad; Q Yan; R C Conaway; J W Conaway
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

4.  SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation.

Authors:  Mingjia Tan; Yongchao Zhao; Sun-Jung Kim; Margaret Liu; Lijun Jia; Thomas L Saunders; Yuan Zhu; Yi Sun
Journal:  Dev Cell       Date:  2011-11-23       Impact factor: 12.270

5.  Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors.

Authors:  Atsuo T Sasaki; Arkaitz Carracedo; Jason W Locasale; Dimitrios Anastasiou; Koh Takeuchi; Emily Rose Kahoud; Sasson Haviv; John M Asara; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Sci Signal       Date:  2011-03-08       Impact factor: 8.192

Review 6.  Novel substrates and functions for the ubiquitin-like molecule NEDD8.

Authors:  Dimitris P Xirodimas
Journal:  Biochem Soc Trans       Date:  2008-10       Impact factor: 5.407

7.  RBX1/ROC1 disruption results in early embryonic lethality due to proliferation failure, partially rescued by simultaneous loss of p27.

Authors:  Mingjia Tan; Shannon W Davis; Thomas L Saunders; Yuan Zhu; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-26       Impact factor: 11.205

8.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 9.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206

Review 10.  Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.

Authors:  Yi Sun; Hua Li
Journal:  Protein Cell       Date:  2012-11-08       Impact factor: 14.870

View more
  43 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo.

Authors:  Xiaochen Zhou; Mingjia Tan; Mukesh K Nyati; Yongchao Zhao; Gongxian Wang; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

3.  The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer.

Authors:  Junfeng Xu; Lihui Li; Guangyang Yu; Wantao Ying; Qiang Gao; Wenjuan Zhang; Xianyu Li; Chen Ding; Yanan Jiang; Dongping Wei; Shengzhong Duan; Qunying Lei; Peng Li; Tieliu Shi; Xiaohong Qian; Jun Qin; Lijun Jia
Journal:  Mol Cell Proteomics       Date:  2014-12-24       Impact factor: 5.911

4.  SAG/Rbx2-Dependent Neddylation Regulates T-Cell Responses.

Authors:  Nathan D Mathewson; Hideaki Fujiwara; Shin-Rong Wu; Tomomi Toubai; Katherine Oravecz-Wilson; Yaping Sun; Corinne Rossi; Cynthia Zajac; Yi Sun; Pavan Reddy
Journal:  Am J Pathol       Date:  2016-08-18       Impact factor: 4.307

5.  The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.

Authors:  Vanessa Vanderdys; Amir Allak; Fadila Guessous; Mouadh Benamar; Paul W Read; Mark J Jameson; Tarek Abbas
Journal:  Mol Cancer Ther       Date:  2017-08-24       Impact factor: 6.261

6.  Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage.

Authors:  Weihua Zhou; Jie Xu; Haomin Li; Ming Xu; Zhijian J Chen; Wenyi Wei; Zhenqiang Pan; Yi Sun
Journal:  Clin Cancer Res       Date:  2016-09-02       Impact factor: 12.531

7.  The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.

Authors:  Liang Zhou; Shuang Chen; Yu Zhang; Maciej Kmieciak; Yun Leng; Lihong Li; Hui Lin; Kathryn A Rizzo; Catherine I Dumur; Andrea Ferreira-Gonzalez; Mohamed Rahmani; Lawrence Povirk; Sri Chalasani; Allison J Berger; Yun Dai; Steven Grant
Journal:  Blood       Date:  2016-02-05       Impact factor: 22.113

Review 8.  Regulation of Mammalian DNA Replication via the Ubiquitin-Proteasome System.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

9.  The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.

Authors:  Yuan Yin; Chuan-Ming Xie; Hua Li; Mingjia Tan; Guoan Chen; Rachel Schiff; Xiufang Xiong; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

10.  MLN4924 neddylation inhibitor promotes cell death in paclitaxel-resistant human lung adenocarcinoma cells.

Authors:  Qiang Xu; Guibin Lin; Huizhe Xu; Lulu Hu; Yupeng Wang; Sha Du; Wuguo Deng; Wenxian Hu; Wei Cheng; Ke Jiang
Journal:  Oncol Lett       Date:  2017-11-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.